Development of a simple and high-yielding fed-batch process for the production of influenza vaccines

Meghrous, Jamal; Mahmoud, Wafaa; Jacob, Danielle; Chubet, Rick; Cox, Manon; Kamen, Amine

doi:10.1016/j.vaccine.2009.10.048

Cited by 40 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, as discussed above, there are clearly timing and capacity constraints and following the 2009 H1N1 pandemic, a perception has arisen that egg-based manufacturing needs to be updated. Possibilities include growing the virus in cell cultures such as MDCK[15], Vero[16] or PER.C6 [17], or by using recombinant DNA technology to express HA and potentially other viral proteins in for example, insect cells (Protein Sciences [18], Novovax [19]), tobacco plants (GreenVax[20], Medicago [21, 22]) or the fungus Neurospora crassa (Neugenesis [22]). Such technologies are potentially better able to respond to the global demand in a pandemic with a more rapid production process and a considerably enhanced surge capacity (see below).…”

Section: The Challenge Of Pandemicsmentioning

confidence: 99%

Vaccine production, distribution, access, and uptake

2011

View full text Add to dashboard Cite

Making human vaccines available on a global scale requires the use of complex production methods, meticulous quality control and reliable distribution channels that ensure the products are potent and effective at their point of use. The technologies involved in manufacturing different types of vaccines may strongly influence vaccine cost, ease of industrial scale-up, stability and ultimately world-wide availability. Manufacturing complexity is compounded by the need for different formulations for different countries and age groups. Reliable vaccine production in appropriate quantities and at affordable prices is the cornerstone of developing global vaccination policies. However, ensuring optimal access and uptake also requires strong partnerships between private manufacturers, regulatory authorities and national and international public health services. For vaccines whose supplies are limited, either due to rapidly emerging diseases or longer-term mismatch of supply and demand, prioritizing target groups can increase vaccine impact. Focusing on influenza vaccines as an example that well illustrates many of the relevant points, this article considers current production, distribution, access and other factors that ultimately impact on vaccine uptake and population-level effectiveness.

show abstract

Section: The Challenge Of Pandemicsmentioning

confidence: 99%

Vaccine production, distribution, access, and uptake

2011

View full text Add to dashboard Cite

show abstract

“…The baculovirus expression system (BEVS) is a powerful tool to produce recombinant protein on both laboratory and industrial scales for various applications such as production of vaccines and pharmaceutical proteins [1,2]. It displays many advantages over other expression systems, including the capacity for large DNA insertion, high expression levels, and post-translational modifications of numerous proteins similar to those in mammalian cells [3,4].…”

Section: Introductionmentioning

confidence: 99%

Rapid baculovirus titration assay based on viable cell side scatter (SSC)

Liu

Pan

et al. 2015

Analytica Chimica Acta

View full text Add to dashboard Cite

“…Initially they have been used to study morphogenesis, life cycle and self -assembly of human and animal viruses [3,43]. Capsid formation and protein-protein interactions were investigated for many different viruses including: rotaviruses [31], picornaviruses [44], caliciviruses [42,45], papilloma viruses [46,47] herpesviruses [32], parvoviruses [48], flaviviruses [38], orthomyxoviruses, including influenza A virus [49] , paramyxoviruses [50] and retroviruses [51].…”

Section: Baculovirus-derived Virus-like Particles (Vlps) As a New Thementioning

confidence: 99%

Application of Baculovirus-Insect Cell Expression System for Human Therapy

Rychłowska

Gromadzka²,

Bieńkowska-Szewczyk³

et al. 2011

CPB

View full text Add to dashboard Cite

A major advantage of recombinant DNA technology is its flexibility allowing for "on demand" production of specific proteins with theurapeutic value in heterologous expression systems. Gene expression vectors based on baculovirus, insect virus attacking mostly lepidopteran species, are frequently used for relatively inexpensive and fast production of such proteins. This expression system is recognized as one of the most powerful technologies for commercial synthesis of glycoproteins originating from vertebrate themselves or from vertebrate viruses. Glycosylation pathways utilized by insects are not identical, though they are similar to vertebrate glycosylation pathways. In the review special attention is given to the development of new virus-like particles (VLPs) potential vaccines which represent a novel class of subunit vaccines that are able to stimulate efficiently cellular and humoral immune responses against viral agents. Apart from production of vertebrate proteins or VLPs "on demand " in insect cells, a new exciting field of using baculovirus as gene delivery system to vertebrate cells was recently open which has a great potential for future uses of baculovirus as effective gene therapy vector.

show abstract

Development of a simple and high-yielding fed-batch process for the production of influenza vaccines

Cited by 40 publications

References 20 publications

Vaccine production, distribution, access, and uptake

Vaccine production, distribution, access, and uptake

Rapid baculovirus titration assay based on viable cell side scatter (SSC)

Application of Baculovirus-Insect Cell Expression System for Human Therapy

Contact Info

Product

Resources

About